These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 8717382

  • 1. Clinical and immunological characteristics of the emulsion form of inactivated influenza vaccine delivered by oral immunization.
    Avtushenko SS, Sorokin EM, Zoschenkova NY, Zacharova NG, Naichin AN.
    J Biotechnol; 1996 Jan 26; 44(1-3):21-8. PubMed ID: 8717382
    [Abstract] [Full Text] [Related]

  • 2. [An immunogenicity and reactogenicity study of a purified, inactivated trivalent influenza vaccine for parenteral administration prepared for the 1996-1997 season].
    Lupulescu E, Ioniţă E, Botez D, Matepciuc M, Tabra ME, Tecu C, Alexandrescu V, Munţiu A.
    Bacteriol Virusol Parazitol Epidemiol; 1997 Jan 26; 42(1-2):110-2. PubMed ID: 9235136
    [No Abstract] [Full Text] [Related]

  • 3. Serum and mucosal immunologic responses in children following the administration of a new inactivated intranasal anti-influenza vaccine.
    Greenbaum E, Furst A, Kiderman A, Stewart B, Levy R, Schlesinger M, Morag A, Zakay-Rones Z.
    J Med Virol; 2001 Sep 26; 65(1):178-84. PubMed ID: 11505461
    [Abstract] [Full Text] [Related]

  • 4. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA.
    Pediatrics; 2006 Sep 26; 118(3):e570-8. PubMed ID: 16950948
    [Abstract] [Full Text] [Related]

  • 5. [Safety and immunogenicity of split vaccines of influenza viruses].
    Zhu CL, Fang HH, Zhu FC, Wang YQ, Wu XL, Xue FB, Shen YJ, Lian JZ.
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2004 Sep 26; 18(3):207-9. PubMed ID: 15640848
    [Abstract] [Full Text] [Related]

  • 6. Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine.
    Greenbaum E, Engelhard D, Levy R, Schlezinger M, Morag A, Zakay-Rones Z.
    Vaccine; 2004 Jun 30; 22(20):2566-77. PubMed ID: 15193382
    [Abstract] [Full Text] [Related]

  • 7. A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness.
    Langley JM, Aoki F, Ward BJ, McGeer A, Angel JB, Stiver G, Gorfinkel I, Shu D, White L, Lasko B, Dzongowski P, Papp K, Alexander M, Boivin G, Fries L.
    Vaccine; 2011 Feb 24; 29(10):1921-8. PubMed ID: 21219987
    [Abstract] [Full Text] [Related]

  • 8. Immunogenicity and tolerability of inactivated flu vaccine in high risk and healthy children.
    Avila Aguero ML, Soriano-Fallas A, Umaña-Sauma MA, Ulloa-Gutierrez R, Arnoux S.
    Medicina (B Aires); 2007 Feb 24; 67(4):351-9. PubMed ID: 17891930
    [Abstract] [Full Text] [Related]

  • 9. Clinico-immunologic and allergologic studies with the inactivated influenza virus vaccine purified and concentrated by gradient centrifugation.
    Subbotina TI, Tenkova TV, Sidorova LV, Shpilyuk GF, Drinevsky VP, Voitsekhovskaya EM, Konstantinov VK, Sominina AA.
    Acta Virol; 1988 Nov 24; 32(6):494-502. PubMed ID: 2906221
    [Abstract] [Full Text] [Related]

  • 10. [Comparative study on safety and immunogenicity between influenza subunit vaccine and split vaccine].
    Dong PM, Li YQ, Zheng TZ, Jia YP, Li F, Han TW, Qiao RX, Zhang BH.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Jul 24; 24(7):570-3. PubMed ID: 12975010
    [Abstract] [Full Text] [Related]

  • 11. [The prospects for using inactivated influenza vaccines on the troops].
    Furgal SM, Degtiarev AA, Korol'kov VF.
    Voen Med Zh; 1993 May 24; (5):35-6, 80. PubMed ID: 8356819
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.
    Fleming DM, Crovari P, Wahn U, Klemola T, Schlesinger Y, Langussis A, Øymar K, Garcia ML, Krygier A, Costa H, Heininger U, Pregaldien JL, Cheng SM, Skinner J, Razmpour A, Saville M, Gruber WC, Forrest B, CAIV-T Asthma Study Group.
    Pediatr Infect Dis J; 2006 Oct 24; 25(10):860-9. PubMed ID: 17006278
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age.
    Baxter R, Patriarca PA, Ensor K, Izikson R, Goldenthal KL, Cox MM.
    Vaccine; 2011 Mar 09; 29(12):2272-8. PubMed ID: 21277410
    [Abstract] [Full Text] [Related]

  • 14. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children.
    Neuzil KM, Jackson LA, Nelson J, Klimov A, Cox N, Bridges CB, Dunn J, DeStefano F, Shay D.
    J Infect Dis; 2006 Oct 15; 194(8):1032-9. PubMed ID: 16991077
    [Abstract] [Full Text] [Related]

  • 15. [Influenza live attenuated intra-nasal vaccines].
    Weil-Olivier C.
    Arch Pediatr; 2010 Jun 15; 17(6):904-5. PubMed ID: 20654953
    [No Abstract] [Full Text] [Related]

  • 16. Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents.
    Lu CY, Shao PL, Chang LY, Huang YC, Chiu CH, Hsieh YC, Lin TY, Huang LM.
    Vaccine; 2010 Aug 16; 28(36):5864-70. PubMed ID: 20600484
    [Abstract] [Full Text] [Related]

  • 17. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections.
    Ashkenazi S, Vertruyen A, Arístegui J, Esposito S, McKeith DD, Klemola T, Biolek J, Kühr J, Bujnowski T, Desgrandchamps D, Cheng SM, Skinner J, Gruber WC, Forrest BD, CAIV-T Study Group.
    Pediatr Infect Dis J; 2006 Oct 16; 25(10):870-9. PubMed ID: 17006279
    [Abstract] [Full Text] [Related]

  • 18. Benefits of increasing the dose of influenza vaccine in residents of long-term care facilities: a randomized placebo-controlled trial.
    Cools HJ, Gussekloo J, Remmerswaal JE, Remarque EJ, Kroes AC.
    J Med Virol; 2009 May 16; 81(5):908-14. PubMed ID: 19319953
    [Abstract] [Full Text] [Related]

  • 19. Safety and immunogenicity of a Proteosome -trivalent inactivated influenza vaccine, given nasally to healthy adults.
    Langley JM, Halperin SA, McNeil S, Smith B, Jones T, Burt D, Mallett CP, Lowell GH, Fries L.
    Vaccine; 2006 Mar 06; 24(10):1601-8. PubMed ID: 16303215
    [Abstract] [Full Text] [Related]

  • 20. A proposal for safety standards for human use of cholera toxin (or Escherichia coli heat-labile enterotoxin) derivatives as an adjuvant of nasal inactivated influenza vaccine.
    Tamura SI, Kurata T.
    Jpn J Infect Dis; 2000 Jun 06; 53(3):98-106. PubMed ID: 10957706
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.